Journal article
Authors list: Gall, Henning; Vachiery, Jean-Luc; Tanabe, Nobuhiro; Halank, Michael; Orozco-Levi, Mauricio; Mielniczuk, Lisa; Chang, MiKyung; Vogtlaender, Kai; Gruenig, Ekkehard
Publication year: 2018
Pages: 313-313
Journal: Lung
Volume number: 196
Issue number: 3
ISSN: 0341-2040
eISSN: 1432-1750
Open access status: Green
DOI Link: https://doi.org/10.1007/s00408-018-0112-z
Publisher: Springer
Abstract:
The original version of this article unfortunately contained a mistake. In the "Results" section, the percentage of patients with inoperable or persistent/recurrent CTEPH included in the study was reported as 85%. This has been corrected to 68% with this erratum.
Citation Styles
Harvard Citation style: Gall, H., Vachiery, J., Tanabe, N., Halank, M., Orozco-Levi, M., Mielniczuk, L., et al. (2018) Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH (vol 196,pg 305,2018), Lung, 196(3), p. 313. https://doi.org/10.1007/s00408-018-0112-z
APA Citation style: Gall, H., Vachiery, J., Tanabe, N., Halank, M., Orozco-Levi, M., Mielniczuk, L., Chang, M., Vogtlaender, K., & Gruenig, E. (2018). Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH (vol 196,pg 305,2018). Lung. 196(3), 313. https://doi.org/10.1007/s00408-018-0112-z
